Delving into the Latest Updates on HC-SVT-1001 with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

Adipose-derived-stem-cells (Salvat)

Target-

Mechanism

Cell replacements

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Pseudarthrosis

Originator Organization

Editorial Salvat SL

Active Organization-

Inactive Organization

Editorial Salvat SL

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) and HC-SVT-1002 (Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones

The purpose os this study is to evaluate the safety and effectiveness of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones.

Start Date10 Nov 2015

Sponsor / Collaborator

Editorial Salvat SL

EUCTR2013-000930-37-ES / Unknown statusPhase 2

A phase II clinical trial to assess the effect of HC-SVT-1001 (autologous fat stem adult mesenchymal cells expanded and combined with a tricalcium phosphate biomaterial) and HC-SVT-1002 (allogeneic fat stem adult mesenchymal cells expanded and combined with a tricalcium phosphate biomaterial) in the surgical treatment of atrophic pseudarthrosis of long bones

Start Date29 Apr 2014

Sponsor / Collaborator-

100 Clinical Results associated with HC-SVT-1001

Login to view more data

100 Translational Medicine associated with HC-SVT-1001

Login to view more data

100 Patents (Medical) associated with HC-SVT-1001

Login to view more data

100 Deals associated with HC-SVT-1001

Login to view more data